Paola trial nejm

Author: ocju

August undefined, 2024

WebSep 28, 2024 · Isabelle L. Ray-Coquard of the Medical Oncology, Centre Léon Bérard in Lyon, GINECO group France presented findings from the PAOLA-1/ENGOT-ov25 trial, … WebAug 1, 2024 · In the Phase III PAOLA-1/ENGOT-ov25 (NCT02477644) trial, the addition of the PARP inhibitor olaparib to bevacizumab maintenance therapy led to a significant progression-free survival (PFS) benefit in patients with newly diagnosed advanced ovarian cancer (hazard ratio [HR] 0.59; 95% confidence interval [CI] 0.49-0.72), particularly in …

Addition of Olaparib to Bevacizumab Maintenance in Advanced …

WebJun 23, 2015 · Randomized, Double-Blind, Phase III Trial of Olaparib vs. Placebo in Patients with Advanced FIGO Stage IIIB - IV High Grade Serous or Endometrioid Ovarian, … Web814MO - Phase II study of olaparib (O) plus durvalumab (D) and bevacizumab (B) (MEDIOLA): Initial results in patients (pts) with non-germline BRCA-mutated (non-gBRCAm) platinum sensitive relapsed (PSR) ovarian cancer (OC) Presenter: Yvette Drew Session: Mini Oral - Gynaecological cancers 2 Resources: Abstract Slides Webcast 18 Sep 2024 process decision program charts

Breakthrough from PAOLA1 GINECO/ENgOT-ov25 trial

WebDec 19, 2024 · BRCA. BRCA mutations (median progression-free survival, 37.2 vs. 17.7 months), and 0.43 (95% CI, 0.28 to 0.66) in patients with HRD-positive tumors that did … WebIn the PAOLA-1/ENGOT-ov25 (NCT02477644) primary analysis, adding ola to maintenance bev after first-line (1L) platinum-based chemotherapy (PBC) + bev led to a significant progression-free survival (PFS) benefit in AOC (HR 0.59, 95% CI 0.49–0.72; P<0.001), particularly in pts with homologous recombination deficiency (HRD+; BRCA1/2 mutation … Web2416 n engl j med 381;25 nejm.orgDecember 19, 2024 The authors’ full names, academic de-grees, and affiliations are listed in the ... PAOLA-1 trial was conducted in 11 countries. process deadlock

Login to your account - The Lancet Oncology

Primary Cytoreductive Surgery With or Without Hyperthermic ...

WebMay 28, 2024 · Background: The Phase III MONALEESA-3 trial (NCT02422615) previously demonstrated a statistically significant improvement in OS with RIB, a cyclin-dependent kinase 4/6 inhibitor (CDK4/6i), plus FUL compared with placebo (PBO) plus FUL as first-line (1L) or second-line (2L) treatment in postmenopausal pts with HR+/HER2− ABC … WebJan 12, 2024 · This randomized, controlled trial evaluated the efficacy and safety of lutetium-177 ( 177 Lu)-Dotatate in patients with advanced, progressive, somatostatin-receptor-positive midgut neuroendocrine tumors. regrowth of the grove wowWebPAOLA-1 is the first and only phase 3 trial to investigate a PARP inhibitor combination regimen against an active and established maintenance therapy: bevacizumab 1-5 In women with HRD-positive * advanced ovarian cancer, following complete or partial response to first-line platinum-based chemotherapy + bevacizumab1 regrowth of the grove p99

"WebMay 28, 2024 · Conclusions: In the PAOLA-1 study, maintenance olaparib + bev provided a PFS and PFS2 benefit over pbo + bev in HRD+ pts, irrespective of FIGO stage and residual disease after upfront surgery. Clinical trial information: NCT02477644. PFS and PFS2 by FIGO stage in HRD+ pts in PAOLA-1. NE, not estimable. " - Paola trial nejm

Paola trial nejm

Phase III PAOLA-1/ENGOT-ov25 trial: olaparib plus

WebOct 29, 2024 · Another new trial, called PAOLA-1, tested the combination of bevacizumab plus olaparib as maintenance therapy. More than 800 women with advanced ovarian cancer whose tumors shrank either completely or … WebIntroduction In the Phase III PAOLA-1/ENGOT-ov25 trial ([NCT02477644][1]), adding maintenance olaparib to bevacizumab improved progression-free survival (PFS) in …

Did you know?

WebJun 2, 2024 · 5562. Background: In the Phase III PAOLA-1/ENGOT-ov25 trial (NCT02477644), maintenance olaparib plus bevacizumab (bev) provided a significant progression-free survival (PFS) benefit, compared with placebo plus bev, in patients (pts) with newly diagnosed advanced ovarian cancer in response after platinum-based … WebSep 10, 2024 · The investigators concluded: “In patients with advanced ovarian cancer receiving first-line standard therapy including bevacizumab, the addition of maintenance …

WebJun 2, 2024 · 5562. Background: In the Phase III PAOLA-1/ENGOT-ov25 trial (NCT02477644), maintenance olaparib plus bevacizumab (bev) provided a significant … WebSep 2, 2024 · Trial Design and Oversight We conducted a phase 3 pragmatic, open-label, parallel-group randomized controlled trial at 22 U.K. NHS hospitals following independent ethics committee approval...

WebMar 16, 2024 · OS did not cross the pre-specified boundary (p<0.01) (Tutt et al NEJM 2024). The second pre-specified analysis of OS and updated IDFS, DDFS and safety descriptive analyses was planned after 330 IDFS events [DCO2 12/07/21; MFU 3.5 years]. Methods WebDec 11, 2024 · The objective of this study is to prove that treatment with primary cytoreductive surgery in combination with HIPEC (treatment arm) improves outcome compared to primary cytoreductive surgery without HIPEC (standard arm) with acceptable morbidity, in patients with FIGO stage III epithelial ovarian cancer who are eligible for …

WebIn the Phase III PAOLA-1/ENGOT-ov25 (NCT02477644) trial, the addition of the PARP inhibitor olaparib to bevacizumab maintenance therapy led to a significant progression-free survival (PFS) benefit in patients with newly diagnosed advanced ovarian cancer (hazard ratio [HR] 0.59; 95% confidence interval [CI] 0.49-0.72), particularly in patients who were …

WebMar 21, 2024 · After long-term follow-up, olaparib (Lynparza) maintenance therapy demonstrated progression-free survival (PFS) benefit in almost half (48%) of the patients with ovarian cancer compared with 21% for those who received placebo, including consistent benefit in high- and low-risk patients. 1 regrowth program riskWebPAOLA-1/ENGOT-ov25 ([NCT02477644][1]) is the first Phase III trial to evaluate the efficacy and safety of a PARP inhibitor with bevacizumab as first-line maintenance … regrowth on a sword tinkersWebIn the primary analysis of PAOLA-1/ENGOT-ov25 (NCT02477644), adding olaparib to maintenance bev after first-line platinum-based chemotherapy with bev led to a significant progression-free survival benefit in advanced HGOC pts (HR 0.59; 95% CI 0.49 -0.72) (Ray-Coquard et al. NEJM 2024); PFS2 was immature. processdefinition.findactivityWebDec 19, 2024 · Conclusions: Among patients with newly diagnosed advanced ovarian cancer who had a response to platinum-based chemotherapy, those who received niraparib had significantly longer progression-free survival than those who received placebo, regardless of the presence or absence of homologous-recombination deficiency. process deer meatWebPurpose: In the initial PALOMA-2 ( NCT01740427) analysis with median follow-up of 23 months, palbociclib plus letrozole significantly prolonged progression-free survival (PFS) in women with estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) [hazard ratio (HR) 0.58; P < 0.001]. regrowthrxWebJun 2, 2024 · Background: In the Phase III PAOLA-1/ENGOT-ov25 trial, the addition of maintenance olaparib (ola) to bevacizumab (bev) in patients (pts) with newly diagnosed … processdefinitionid parameter is requiredWebJul 25, 2024 · Our trial was designed to prospectively confirm the findings seen in Study 19 in a similar disease setting: it is an international, multicentre, randomised, phase 3 trial to evaluate olaparib maintenance … process definition peoplesoft